4.7 Article

FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Medicine, General & Internal

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

Shanu Modi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Review Oncology

HER2-Low Breast Cancer: Pathological and Clinical Landscape

Paolo Tarantino et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Article Medicine, General & Internal

Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

Sandra M. Swain et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Article Oncology

US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status

Nadia Howlader et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)

Article Medicine, General & Internal

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

Sunil Verma et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Letter Oncology

Treatment of breast cancer with trastuzumab during pregnancy

Shubham Pant et al.

JOURNAL OF CLINICAL ONCOLOGY (2008)

Article Medicine, General & Internal

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

Charles E. Geyer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2006)